Spectrum Pharmaceuticals — Proxy Contest (June 2016)
10 slides from Spectrum Pharmaceuticals's proxy contest presentation, Jun 2, 2016
Slide 1: Spectrum Pharmaceuticals June 2016
Spectrum Pharmaceuticals June 2016
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current b
Slide 3: Spectrum is a Biotech Company Focused on Bringing Cancer Treatments to Patients in Need
Spectrum currently markets six oncology/hematology products that target rare types of cancer such as advanced metastatic colorectal cancer, acute lymphoblastic leukemia, multiple myeloma and non-Hodgkin’s lymphoma Spectrum has no drug-discovery program. However, we have acquired and are also dev
Slide 4: Spectrum has been successful at Acquiring and Advancing Drugs to Treat Cancer
4 Spectrum has been successful at Acquiring and Advancing Drugs to Treat Cancer 2013 • Acquired rights for Apaziquone • In-licensed Evomela • Acquired Talon Therapeutics • Filed Beleodaq NDA with FDA 2014 • Beleodaq NDA Approved by FDA • Out-Licensed rights for 3 drugs to CASI Pharma • Filed Evomela
Slide 5: Committed to Sound Corporate Governance
All directors elected annually Continuing changes to Governance Practices o Adopted Corporate Governance Guidelines on April 1, 2015. o Adopted Stock Ownership Policy on April 1, 2015. o Adopted Anti-Hedging Policy on April 1, 2015. o Amended our 2009 Incentive Award Plan effective April 15, 201
Slide 6: Compensation Program Evolution in 2016
6 Compensation Program Evolution in 2016 • During 2015, we spoke with stockholders representing over 50% of our outstanding shares gathering feedback. • Based on Shareholder feedback, the Compensation Committee independently retained a compensation consultant to advise on best practices for executiv
Slide 7: New Peer Group
7 New Peer Group AMAG Pharmaceuticals, Inc. Enanta Pharmaceuticals, Inc. Albany Molecular Research Inc. Sequenom Inc. Affymetrix, Inc. Ariad Pharmaceuticals, Inc. Sagent Pharmaceuticals, Inc. Fluidigm Corp. Genomic Health Inc. Harvard Bioscience Inc. Aegerion Pharmaceuticals, Inc. Vanda Pharmaceutic
Slide 8: Compensation Plan Structure
8 Compensation Plan Structure Base Salary • To attract and retain talent in a highly competitive labor market • Based on pay levels of comparable positions within peer group, as well as qualifications, experience and role characteristics • Merit increases based on individual performance and size of
Slide 9: CEO Compensation Overview
9 CEO Compensation Overview *Guaranteed pay is only 27% of total compensation * *
Slide 10: We Seek Your Support at Our Annual Meeting 2016
10 We Seek Your Support at Our Annual Meeting 2016 Spectrum Pharmaceuticals Management Recommendations FOR Election of Directors FOR Advisory vote to approve the compensation of our named executive officers FOR Ratification of the appointment of an independent registered public accounting firm